Similar to VMs, pharmacological treatments that target the PI3K-AKT-mTOR and RAS-MAPK pathway are used for LM and, in the future, drugs targeting VEGFR or VEGFC itself might be suitable to shrink LM lesions [267]. This evidence concerns the gene MTOR and lymphangioma.